evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

14 questions · 14 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 6 · 42.9%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 7.1%Moderate 4 · 28.6%High 3 · 21.4%

Febuxostat 120 mg/day vs placebo

Acute gout attacks · patients with chronic cout

Febuxostat 120 mg/day probably leads to higher incidence of gout flares compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs placebo

Serum uric acid <6.0 mg/dL at final visit · patients with chronic cout

Febuxostat 120 mg/day may leads to higher serum uric acid <6.0 mg/dL at final visit compared with placebo (low certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs placebo

Serious adverse events · patients with chronic cout

Febuxostat 120 mg/day showed no clear difference in serious Adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs placebo

Withdrawals due to adverse events · patients with chronic cout

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs allopurinol

Serum uric acid <6.0 mg/dL at final visit · people with chronic gout

Febuxostat 120 mg/day probably leads to higher serum uric acid <6.0 mg/dL at final visit compared with allopurinol (moderate certainty).

1 finding from 1 review

Febuxostat 120 mg/day vs allopurinol

Withdrawals due to adverse events · people with chronic gout

Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).

1 finding from 1 review